EGFR

Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD
GPCR & G Protein

5-HT Receptor Adenosine Receptor Adenylate Cyclase Adrenergic Receptor Angiotensin Receptor APJ Bombesin Receptor Bradykinin Receptor cAMP Cannabinoid Receptor CaSR CCK receptor CCR CGRP Receptor CRFR CXCR Dopamine Receptor EBI2 Endothelin Receptor Formyl Peptide Receptor Free Fatty Acid Receptor G protein-coupled Bile Acid Receptor GCGR GHSR GLP Receptor Glucagon Receptor GnRH Receptor GPCR19 GPR GPR109A Guanylate Cyclase Hedgehog(Smoothened) ROCK Histamine Receptor ICMT Leukotriene Receptor LPA Receptor LPL Receptor LTR mAChR Melanocortin Receptor Melatonin Receptor mGluR Motilin Receptor MRGPR MT Receptor Neurokinin Receptor Neuropeptide Y Receptor Neurotensin Receptor NPY receptor Opioid Receptor OX Receptor Oxytocin Receptor P2Y Receptor PAFR PAR PKD PKG Prostaglandin Receptor Ras RGS Protein S1P Receptor SGLT Sigma Receptor Somatostatin Receptor TAAR TSH Receptor Urotensin Receptor Vasopressin Receptor

+MORE

EGFR

The epidermal growth factor receptor (EGFR; ErbB1) is a member of the epidermal growth factor RTK (receptor tyrosine kinases) family, which also includes HER2/neu (ErbB2), ErbB3 (HER3), and ErbB4 (HER4). The extracellular ligand-binding ectodomain, the single chain transmembrane domain, and the intracellular tyrosine kinase domain make up the EGFR, which is located at the cell surface. Epidermal growth factor (EGF), transforming growth factor (TGF-), amphiregulin, heparin-binding EGF, and betacellulin are just a few of the ligands that bind to and activate the EGFR.

The tyrosine kinase domain is activated by the receptors' formation of homo- or heterodimeric complexes after ligand binding. The Ras-Raf-MAP kinase, PI-3K/Akt, PKC, and Stat/Jak signaling pathways are all activated as a result of the dimerization and autophosphorylation of EGFR. The EGFR is activated to control cellular survival, differentiation, and proliferation. The EGFR has been derided as a proto-oncogene primarily because of its function in encouraging cell proliferation and preventing apoptosis.

EGFR related products

Cat No.	Product Name	CAS No.	Product Description
V0207	Chrysophanic Acid (Chrysophanol)	481-74-3	Chrysophanic acid (also called Chrysophanol), a naturally occuring anthraquinone isolated from Dianella longifolia, is a selective and potent inhibitor of EGFR/mTOR (epidermal growth factor (EGF) receptor/mammalian target of rapamycin) with potential anti-obesity and antitumor activity.
V0543	CL-387785 (EKI-785)	194423-06-8	CL-387785 (CL387785; WAY-EKI 785; EKI 785; EKI785) is a novel, potent, covalent / irreversible, and selective EGFR inhibitor with potential anticancer activity.
V0548	CNX-2006	1375465-09-0	CNX-2006 (CNX2006), a CO-1686 analog, is a covalent / irreversible and mutant-selective EGFR inhibitor with potential antitumor activity.
V0557	CP-724714	537705-08-1	CP-724714 (CP724714) is an orally bioavailable,potent, selective inhibitor of HER2/ErbB2 with potential anticancer activity.
V0558	Dacomitinib (PF-299804, PF-299)	1110813-31-4	Dacomitinib (formerly aslo known as PF299804, PF299; trade name:Vizimpro) is an orally bioavailable, highly selective, irreversible/covalent, 2nd generation pan-ErbB inhibitor, mostly to EGFR, with IC50 values of 6 nM, 45.7 nM and 73.7 nM for inhibiting EGFR,ERBB2, andERBB4, respectively in cell-free assays.
V19109	Dacomitinib hydrate (PF-00299804; PF-299804)	1042385-75-0	escription: Dacomitinib (aslo known as PF299804, PF299; trade name: Vizimpro) is a novel, potent, orally bioavailable, highly selective, irreversible, second generation pan-ErbB inhibitor, mostly to EGFR with with IC50 of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively in cell-free assays.
V4000	EBE-A22	229476-53-3	EBE-A22 is aN-methyl derivative of PD-153035 which exhibits a very high affinity and selectivity for the epidermal growth factor receptor tyrosine kinase (EGF-R TK) and shows a remarkable cytotoxicity against several types of tumor cell lines.
V0544	Erlotinib (OSI744, Tarceva)	183321-74-6	Erlotinib (formerly OSI744, trade name:Tarceva) isa quinazoline-based EGFR (epidermal growth factor receptor) inhibitor with potential antineoplastic activity.
V0533	Erlotinib HCl (OSI-744, Tarceva)	183319-69-9	Erlotinib HCl (formerly OSI-744, OSI744; trade name:Tarceva), the hydrochloride salt of erlotinib, is an EGFR (epidermal growth factor receptor) inhibitor with antitumor activity.
V0534	Gefitinib (ZD 1839)	184475-35-2	Gefitinib (formerly ZD1839, ZD-1839 or trade name: Iressa) is a potent and orally bioavailable EGFR inhibitor with potential anticancer activity.
V0571	Genistein (NPI031L; BIO-00; G2535; PTI G-4660; SIPI9764I)	446-72-0	Genistein (NPI-031L;BIO-300; G-2535; PTI-G-4660; SIPI-9764I), a naturally occuring isoflavonoid isolated from soy products, is a potent multi-kinase inhibitor with potential anticancer activity against various cancers.
V0569	Icotinib (BPI2009)	610798-31-7	Icotinib (formerly known as BPI-2009; trade name Conmana), a side chain-cyclized form of erlotinib, is an orally available and specific EGFR inhibitor with potent anticancer activity.
V3302	Icotinib Hydrochloride (BPI-2009)	1204313-51-8	Icotinib HCl (formerly known as BPI-2009 HCl), the hydrochloride salt ofIcotinib and an macrocyclic analog of erlotinib, is an orally bioavailable, potent and specific EGFR inhibitor with IC50 of 5 nM, including the EGFR, EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R).
V40813	JBJ-04-125-02 HCL	2140807-05-0	JBJ-04-125-02 HCL is a novel, highly potent, mutant-specific, allosteric and orally bioavailable EGFR inhibitor with an IC50 of 0.26 nM for EGFRL858R/T790M.
V0540	Lapatinib (GW-572016, Tykerb, Tyverb)	231277-92-2	Lapatinib (formerly GW572016, trade namesTykerb&Tyverb), usually used in the Ditosylate form, is a potent, orally bioavailable dual EGFR/ErbB2 inhibitor with potential anticancer activity.
V0535	Lapatinib Ditosylate (GW-572016, Tykerb)	388082-77-7	Lapatinib Ditosylate (formerly GW-572016, GW572016; trade names Tykerb and Tyverb) is an orally bioavailable medication acting as an EGFR (epidermal growth factor receptor) and ErbB2 inhibitor with antineoplastic activity.
V3697	Lazertinib (YH25448,GNS-1480)	1903008-80-9	Lazertinib (formerly known as GNS-1480; YH-25448; GNS1480; YH25448;LECLAZA) is an oral, highly mutant-selective and irreversible 3rd generation EGFR TKI (Tyrosine-kinase inhibitors) approved in 2021 for the treatment of lung cancer (NSCLC).
V3179	Lifirafenib (BGB-283)	1446090-79-4	Lifirafenib (formerly BGB-283, Beigene-283) is a potent inhibitor of theRAF kinasesandEGFRin biochemical assays withIC50values of 23, 29 and 495 nM for the recombinant BRAFV600E kinase domain, EGFR and EGFR T790M/L858R mutant respectively.
V37850	Mobocertinib (TAK788, AP32788)	1847461-43-1	Mobocertinib (TAK-788; AP-32788; Exkivity), a drug used for the treatment of non-small cell lung cancer (NSCLC), is a novel, highly potent, irreversible and orally bioavailable inhibitor of EGFR and HER2 oncogenic mutants (e.g. exon 20 insertions), and exhibits high selectivity over WT EGFR.
V11726	Naquotinib free base	1448232-80-1	Naquotinib (ASP 8273; ASP-8273; ASP8273) is an irreversible/covalent and 3rd-generation inhibitor of epidermal growth factor receptor (EGFR) with potential antitumor activity.